MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

3.47 2.66

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.45

Max

3.48

Põhinäitajad
By Trading Economics
Sissetulek	-31M -14M
Müük	-32M 41M
Aktsiakasum	-0.22
Kasumimarginaal	-34.333
Töötajad	293
EBITDA	-37M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+63.87% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	98M 221M
Eelmine avamishind	0.81
Eelmine sulgemishind	3.47

Uudiste sentiment

By Acuity

50%

135 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. apr 2026, 23:48 UTC

Uudisväärsed sündmused

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19. apr 2026, 23:36 UTC

Uudisväärsed sündmused

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19. apr 2026, 22:47 UTC

Uudisväärsed sündmused

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19. apr 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19. apr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19. apr 2026, 23:38 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19. apr 2026, 23:12 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19. apr 2026, 23:10 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19. apr 2026, 23:09 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19. apr 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18. apr 2026, 01:00 UTC

Uudisväärsed sündmused

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

63.87% tõus

12 kuu keskmine prognoos

Keskmine 5.67 USD 63.87%

Kõrge 9 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

135 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.